secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001628280-23-007636
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics reports FY2022 net loss $54.2M; cash $129M; pipeline advancing
--------------------------------------------------------------------------------

- Net loss for FY2022 $54.2M ($0.77 per share) vs net income $122.8M ($1.78) in 2021, driven by prior Takeda milestone.
- Cash and equivalents $129.0M; expected to fund operations into first half of 2025.
- OV329 Phase 1 trial on track; full data with biomarker efficacy proxy expected H1 2024.
- Takeda reaffirms soticlestat regulatory filings in FY2024; Ovid eligible for up to $660M milestones plus royalties.
- Added epileptologist Manoj Malhotra and co-inventor Toshiya Nishi to leadership in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828023007636/0001628280-23-007636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828023007636/ovid-20230313.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-007636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer